問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1712Cases

2021-12-04 - 2023-12-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2022-03-31 - 2023-09-07

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting5Sites

Terminated2Sites

2023-01-01 - 2023-01-24

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Terminated7Sites

2016-02-01 - 2017-12-31

Phase IV

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Terminated8Sites

2024-12-01 - 2029-03-31

Phase II

Active
A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Treatment Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Participated in a Previous Bepirovirsen Treatment Study

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    NA

Participate Sites
6Sites

Recruiting6Sites

2018-04-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy

  • Condition/Disease

    Moderately to Severely Active Crohn's Disease

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
4Sites

Recruiting3Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2018-12-01 - 2024-12-31

Phase III

Completed
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER

  • Condition/Disease

    EARLY HER2-POSITIVE BREAST CANCER

  • Test Drug

    Atezolizumab

Participate Sites
5Sites

Terminated4Sites

王惠暢
China Medical University Hospital

Division of General Surgery

2024-03-01 - 2026-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2023-09-15 - 2025-10-22

Phase III

Completed
Efficacy and safety of semaglutide 2.4 mg once-weekly in adults with overweight and obesity (STEP 12)

  • Condition/Disease

    overweight and obesity

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2017-08-01 - 2022-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 91 92 93 94 95 172
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB